Triplet Therapy with PD-1 Blockade, Histone Deacetylase Inhibitor, and DNA Methyltransferase Inhibitor Achieves Radiological Response in Refractory Double-Expressor Diffuse Large B-cell Lymphoma with 17p Deletion

<div>Immunohistochemical characteristics of tumor cells. (a) Transbronchial biopsy of the mediastinal mass (H&amp;E staining) showing a diffuse proliferation of atypical medium- to large-sized lymphoid cells. (b) CD20-positive neoplastic cells from mediastinal biopsy aspirate. (c) BCL6-positive neoplastic cells (70%) from mediastinal biopsy aspirate. (d) BCL2-positive neoplastic cells (95%) from mediastinal biopsy aspirate. (e) P53-positive neoplastic cells from mediastinal biopsy aspirate. (f) PD-L1-positive neoplastic cells from mediastinal biopsy aspirate.</div>

Case Reports in Hematology

fig2

Figure 2

Figure 2: Triplet Therapy with PD-1 Blockade, Histone Deacetylase Inhibitor, and DNA Methyltransferase Inhibitor Achieves Radiological Response in Refractory Double-Expressor Diffuse Large B-cell Lymphoma with 17p Deletion 

Figure 2 | Triplet Therapy with PD-1 Blockade, Histone Deacetylase Inhibitor, and DNA Methyltransferase Inhibitor Achieves Radiological Response in Refractory Double-Expressor Diffuse Large B-cell Lymphoma with 17p Deletion 